Key Takeaway: The article discusses the ongoing focus on amyloid as a target in developing next-generation Alzheimer's treatments. Cognition Therapeutics emphasizes the importance of understanding third-party content related to this area. However, the article does not provide specific details or updates on treatments or research.
Price reaction · baseline $2.38 (2024-06-12 close) · hit after-hours · clean, no other CGTX news in the window
day 0 close
-7.6%
day 1
-8.8%
day 3 · peak
-15.5%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
You are now leaving the Cognition Therapeutics website
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.